REBOTEC MEDICAL: what changed
REBOTEC MEDICAL
Largest movements
- Receivables within one year +€16,815
up €16,815 (+38.4%), from €43,751 to €60,565
of which Trade receivables: +€16,815
- Cash +€5,155
up €5,155 (+92.6%), from €5,569 to €10,724
mainly Other debts (+€27,221) and Net result for the year (+€22,859)
- Trade debts -€28,426
down €28,426 (-85.3%), from €33,329 to €4,903
- Other debts +€27,221
up €27,221 (+461%), from €5,903 to €33,124
- Profit (loss) carried forward +€22,859
up €22,859, from -€5,199 to €17,660
- Gross operating margin +€40,301
up €40,301, from -€14,761 to €25,540
- Financial income -€1,788
no longer reported in 2025 (was €1,788)
- Financial charges +€1,146
up €1,146 (+170%), from €673 to €1,819
- Depreciation -€398
down €398 (-55.7%), from €715 to €316
- Other operating charges -€260
down €260 (-32.3%), from €806 to €546
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €52,633 | €74,287 | +€21,653 | +41.1% |
| Fixed assets | 21/28 | €3,314 | €2,998 | -€316 | -9.5% |
| Tangible fixed assets | 22/27 | €814 | €498 | -€316 | -38.9% |
| Plant, machinery and equipment | 23 | €814 | €498 | -€316 | -38.9% |
| Financial fixed assets | 28 | €2,500 | €2,500 | = | 0.0% |
| Current assets | 29/58 | €49,319 | €71,289 | +€21,970 | +44.5% |
| Amounts receivable within one year | 40/41 | €43,751 | €60,565 | +€16,815 | +38.4% |
| Trade receivables | 40 | €41,243 | €58,057 | +€16,815 | +40.8% |
| Other amounts receivable | 41 | €2,508 | €2,508 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €5,569 | €10,724 | +€5,155 | +92.6% |
| Total equity and liabilities | 10/49 | €52,633 | €74,287 | +€21,653 | +41.1% |
| Equity | 10/15 | €13,401 | €36,260 | +€22,859 | +171% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€5,199 | €17,660 | +€22,859 | |
| Amounts payable | 17/49 | €39,232 | €38,027 | -€1,206 | -3.1% |
| Amounts payable within one year | 42/48 | €39,232 | €38,027 | -€1,206 | -3.1% |
| Trade debts | 44 | €33,329 | €4,903 | -€28,426 | -85.3% |
| Suppliers | 440/4 | €33,329 | €4,903 | -€28,426 | -85.3% |
| Other amounts payable | 47/48 | €5,903 | €33,124 | +€27,221 | +461% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €715 | €316 | -€398 | -55.7% |
| Other operating charges | 640/8 | €806 | €546 | -€260 | -32.3% |
| Gross operating margin | 9900 | -€14,761 | €25,540 | +€40,301 | |
| Operating profit (loss) | 9901 | -€16,281 | €24,678 | +€40,959 | |
| Financial income | 75/76B | €1,788 | - | -€1,788 | |
| Recurring financial income | 75 | €1,788 | - | -€1,788 | |
| Financial charges | 65/66B | €673 | €1,819 | +€1,146 | +170% |
| Recurring financial charges | 65 | €673 | €1,819 | +€1,146 | +170% |
| Profit (loss) for the period before taxes | 9903 | -€15,167 | €22,859 | +€38,026 | |
| Profit (loss) for the period | 9904 | -€15,167 | €22,859 | +€38,026 | |
| Profit (loss) for the period to be appropriated | 9905 | -€15,167 | €22,859 | +€38,026 |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 4 November 2026 via checked.be.